Inphasol

Our flagship platform for protein delivery PIPER seeks to solve critical bottlenecks in therapeutic protein delivery and industrial recombinant protein production. The therapeutic protein and peptide market is growing rapidly with novel therapeutic peptides being developed and discovered each day. However, existing and novel protein therapeutics suffer from poor bioavailability, poor stability, and expensive manufacturing and purification processes. By allowing colonizing probiotic cell factories to express therapeutics past biologic barriers to delivery, efficacy and cost of protein therapeutics can be drastically improved. Our initial de-risking pipeline focuses on continuous expression of GLP-1 in the intestine for a low-cost approach for obesity and diabetes treatment.